Cutia Therapeutics (2487) AI Stock Analysis

• Market Cap: HK$1.86B
• Dividend Yield: N/A
• Average Volume (3M): 399.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: 25.89%
• EPS Growth: 12.90%
• Country: HK
• Employees: 333
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.83
• Shares Outstanding: 364,730,870
• 10 Day Avg. Volume: 272,590
• 30 Day Avg. Volume: 399,603
• PEG Ratio: 0.06
• Price to Book (P/B): 2.00
• Price to Sales (P/S): 6.98
• P/FCF Ratio: -4.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.76
• Revenue Forecast (FY): HK$742.17M

• Rating: 41 Neutral
• Price Target: HK$4.50 ▼(-1.96% Downside)
• Action: Reiterated Date: 11/22/25
• Date: Action: Reiterated 11/22/25

Cutia Therapeutics faces significant challenges with profitability and cash flow, which heavily impact its financial performance score. The technical analysis indicates bearish momentum, and valuation metrics are unfavorable due to negative earnings. These factors collectively result in a low overall stock score.

Positive Factors

Revenue Growth

Sustained revenue growth near 26% demonstrates improving commercial traction and product uptake. Over a 2–6 month horizon this supports reinvestment in R&D and operations, reduces execution risk, and increases the odds management can scale toward durable profitability if growth persists.

Balance Sheet Improvement

Recovery to positive stockholders' equity and relatively low leverage materially improves solvency and financial flexibility. This durable improvement reduces bankruptcy risk, enhances ability to fund trials or commercialization, and supports multi-quarter planning versus peers with weak equity.

Orphan/ Specialized Focus

Concentrating on rare and complex diseases creates structural advantages—regulatory incentives, pricing power, and smaller targeted populations—which can produce higher margin, more defensible franchises over time. This business model supports durable revenue per approved product.

Negative Factors

Negative Cash Flow

Persistent negative operating and free cash flow constrains internal funding for trials and commercialization, forcing ongoing reliance on external capital. Over several months this raises dilution or interest costs, limits strategic optionality, and can delay development milestones if financing is tight.

Sustained Losses and Weak Margins

Despite revenue gains, continued negative net income and EBIT margins reflect high operating and R&D spend that erode profitability. Without structural margin improvement or scalable cost control, losses may persist and necessitate external funding, constraining long-term capital allocation and growth.

Equity Volatility

A history of fluctuating equity—though recently recovered—signals instability in the capital structure. Recurring swings can weaken borrowing capacity, deter partnership or licensing negotiations, and complicate multi-quarter planning as management balances financing needs against dilution and credibility concerns.

Cutia Therapeutics Business Overview & Revenue Model

Company Description

Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.

How the Company Makes Money

Cutia Therapeutics generates revenue primarily through the sale of its pharmaceutical products, which are marketed to healthcare providers and institutions. The company also engages in strategic partnerships with other biotech firms and pharmaceutical companies, allowing for collaborative research and development efforts, as well as sharing of resources and expertise. Additionally, Cutia may benefit from milestone payments and royalties from licensing agreements related to its proprietary technologies and drug candidates. Grants and funding from public or private entities may also contribute to its revenue, especially during the research and development phases of its products.

Cutia Therapeutics Financial Statement Overview

Summary

Cutia Therapeutics is experiencing significant revenue growth but faces challenges with profitability and cash flow management. The balance sheet shows improvement in equity, yet consistent profitability and positive cash flows are necessary for financial stability.

Income Statement

Cutia Therapeutics shows significant revenue growth, with a notable increase from 2021 to 2024. However, the company is experiencing substantial losses, as indicated by negative net income and EBIT margins. The gross profit margin is positive, but the net profit margin remains negative, highlighting ongoing profitability challenges.

Balance Sheet

The balance sheet reflects a strong equity position with a positive stockholders' equity in 2024, recovering from negative equity in previous years. The debt-to-equity ratio is relatively low, indicating manageable leverage. However, the company has faced fluctuating equity levels, which could pose risks if not stabilized.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, indicating cash management challenges. Despite improvements in free cash flow from 2023 to 2024, the company still faces difficulties in generating positive cash flow, which could impact its financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	250.33M	279.62M	137.62M	11.37M	2.04M
Gross Profit	125.19M	143.46M	71.01M	7.94M	1.61M
EBITDA	-422.82M	-430.69M	-1.92B	-535.19M	-309.23M
Net Income	-472.27M	-433.81M	-1.96B	-555.84M	-319.58M
Balance Sheet
Total Assets	1.12B	1.39B	1.71B	1.45B	1.49B
Cash, Cash Equivalents and Short-Term Investments	681.51M	876.15M	1.27B	1.08B	1.38B
Total Debt	290.40M	320.94M	243.75M	54.13M	26.53M
Total Liabilities	359.62M	418.51M	357.76M	2.69B	2.29B
Stockholders Equity	756.62M	974.73M	1.35B	-1.25B	-790.51M
Cash Flow
Free Cash Flow	-209.64M	-468.66M	-437.23M	-371.50M	-185.76M
Operating Cash Flow	-196.82M	-442.98M	-381.31M	-236.19M	-159.88M
Investing Cash Flow	272.88M	316.07M	-203.58M	462.06M	-410.65M
Financing Cash Flow	32.50M	37.84M	588.32M	-10.25M	480.76M

Cutia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.59
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2487, the sentiment is Positive. The current price of 4.59 is below the 20-day moving average (MA) of 4.85, below the 50-day MA of 4.85, and below the 200-day MA of 7.68, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 55.42 is Neutral, neither overbought nor oversold. The STOCH value of 70.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2487.

Cutia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1873	55 Neutral	HK$5.08B	7.02	4.45%	―	-8.11%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3681	45 Neutral	HK$2.53B	-10.54	-66.18%	―	-100.00%	30.68%
2179	44 Neutral	HK$2.06B	-2.54	-129.05%	―	―	-18.99%
2616	42 Neutral	HK$10.36B	-9.27	-71.29%	―	-55.64%	-158.67%
2487	41 Neutral	HK$1.86B	-3.04	-48.42%	―	25.89%	12.90%
1167	37 Underperform	HK$5.45B	-31.16	-5.10%	―	770.20%	87.27%

Cutia Therapeutics Corporate Events

Cutia Therapeutics’ Botulinum Toxin CU-20101 Meets Phase III Goals in China

Cutia Therapeutics announced that its investigational product CU-20101, a botulinum toxin type A injection for treating moderate to severe glabellar lines, has delivered positive topline results in a Phase III clinical trial in China. In a randomized, multi-center, double-blind trial with BOTOX as the reference drug, CU-20101 met primary and secondary efficacy endpoints by demonstrating non-inferiority in wrinkle reduction across investigator, participant and independent committee assessments, and showed a favorable safety profile comparable to BOTOX with no treatment-related serious adverse events. Manufactured without animal-derived materials, CU-20101 is expected to offer safety advantages by eliminating certain infection and allergy risks, and, if successfully developed and commercialized, would further strengthen Cutia’s dermatology portfolio and support its efforts to gain share in China’s fast-growing aesthetic medicine market.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics Reshapes Board with Resignation of Dr. Huang and Appointment of Veteran Executive Lu Minfang

Cutia Therapeutics announced that non-executive director Dr. Huang Xiao will resign from the board with effect from 30 December 2025 to focus on personal commitments, with both the company and Dr. Huang confirming there are no disagreements or issues requiring shareholder attention. On the same date, the company will appoint industry veteran Mr. Lu Minfang, a partner at Yunfeng Investment Management and former chief executive of China Mengniu Dairy, as a non-executive director for an initial three‑year term without director’s fees, bringing extensive leadership and consumer-sector experience that may strengthen Cutia’s governance and strategic positioning.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics Updates Board and Committee Structure

Cutia Therapeutics has announced the latest composition of its board of directors, comprising executive directors Zhang Lele and Huang Yuqing, several non-executive directors, and three independent non-executive directors. The company has also detailed the membership and chairmanship of its three key board committees—Audit, Remuneration and Nomination—indicating which directors serve as members and which act as chairpersons, underscoring its emphasis on formalized governance and oversight structures as it continues to operate as a listed entity in Hong Kong.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics’ Topical Finasteride Spray Gains Regulatory Acceptance

Cutia Therapeutics has announced that their Abbreviated New Drug Application for CU-40105, a self-developed topical finasteride spray for treating androgenetic alopecia, has been accepted by China’s National Medical Products Administration. This development is expected to enhance the company’s product offerings in scalp disease treatments, potentially allowing for a differentiated commercialization strategy and broader market coverage. The acceptance marks a significant step in expanding their product matrix and targeting diverse consumer needs in the androgenetic alopecia market.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics’ Acne Treatment Shows Promising Early Results

Cutia Therapeutics announced that a post-hoc analysis of their Phase III clinical trial for CU-10201, a topical 4% minocycline foam, has been accepted for presentation at the 20th CDA Annual Meeting. The analysis revealed that CU-10201 demonstrates a rapid onset of action in treating moderate to severe facial acne vulgaris in Chinese patients, showing significant improvement in inflammatory lesions within the first two weeks of treatment. This suggests that CU-10201 could become a significant treatment option for acne vulgaris, enhancing the company’s position in the dermatological market.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.